PT - JOURNAL ARTICLE AU - Marais, Gert AU - Hsiao, Nei-yuan AU - Iranzadeh, Arash AU - Doolabh, Deelan AU - Enoch, Annabel AU - Chu, Chun-yat AU - Williamson, Carolyn AU - Brink, Adrian AU - Hardie, Diana TI - Saliva swabs are the preferred sample for Omicron detection AID - 10.1101/2021.12.22.21268246 DP - 2021 Jan 01 TA - medRxiv PG - 2021.12.22.21268246 4099 - http://medrxiv.org/content/early/2021/12/24/2021.12.22.21268246.short 4100 - http://medrxiv.org/content/early/2021/12/24/2021.12.22.21268246.full AB - The Omicron variant is characterised by more than 50 distinct mutations, the majority of which are located in the spike protein. The implications of these mutations for disease transmission, tissue tropism and diagnostic testing are still to be determined. We evaluated the relative performance of saliva and mid-turbinate swabs as RT-PCR samples for the Delta and Omicron variants. The positive percent agreement (PPA) of saliva swabs and mid-turbinate swabs to a composite standard was 71% (95% CI: 53-84%) and 100% (95% CI: 89-100%), respectively, for the Delta variant. However, for the Omicron variant saliva and mid-turbinate swabs had a 100% (95% CI: 90-100%) and 86% (95% CI: 71-94%) PPA, respectively. This finding supports ex-vivo data of altered tissue tropism from other labs for the Omicron variant. Reassessment of the diagnostic testing standard-of-care may be required as the Omicron variant become the dominant variant worldwide.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded in whole, or in part, by Wellcome [203135/Z16/Z]. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. This study was funded in whole, or in part, by National Health Laboratory Service in South Africa.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research has been approved by the University of Cape Town Human Research Ethics Committee (Ref: 420/2020).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.